Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation
| Title | Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation |
| Publication Type | Journal Article |
| Year of Publication | 2016 |
| Authors | Unzue A., Lafleur K., Zhao H., Zhou T., Dong J., Kolb P., Liebl J., Zahler S., Caflisch A., Nevado C. |
| Journal | European Journal of Medicinal Chemistry |
| Volume | 112 |
| Start Page | 347 |
| Pagination | 347-366 |
| Date Published | 2016 Apr 13 |
| Type of Article | Review Article |
| Keywords | Animals, Computer Simulation, Drug Design, Humans, Isoquinolines, Neoplasms, Protein Kinase Inhibitors, Quinoxalines, Receptor, EphB2, Structure-Activity Relationship, Xanthine |
| Abstract | Several selective and potent EphB4 inhibitors have been discovered, optimized and biophysically characterized by our groups over the past years. On the outset of these discoveries high throughput docking techniques were applied. Herein, we review the optimization campaigns started from three of these hits (Xan-A1, Pyr-A1 and Qui-A1) with emphasis on their in depth in vitro and in vivo characterization, together with previously unpublished angiogenesis and fluorescence based assays. |
| DOI | 10.1016/j.ejmech.2016.01.057 |
| pubindex | 0208 |
| Alternate Journal | Eur. J. Med. Chem. |
| PubMed ID | 26907157 |
Full Text PDF:
SI PDF:
Highlight Role:
Drug Design